Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2025 value amounting to -$1000.0.

  • Ernexa Therapeutics' Change in Receivables rose 9756.1% to -$1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$34000.0, marking a year-over-year increase of 9786.16%. This contributed to the annual value of $12000.0 for FY2024, which is 10227.7% up from last year.
  • Ernexa Therapeutics' Change in Receivables amounted to -$1000.0 in Q3 2025, which was up 9756.1% from -$2000.0 recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Change in Receivables ranged from a high of $792000.0 in Q3 2023 and a low of -$1.4 million during Q4 2023
  • Moreover, its 5-year median value for Change in Receivables was -$3000.0 (2021), whereas its average is -$33812.5.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 375000.0% in 2022, then tumbled by 550800.0% in 2023.
  • Over the past 5 years, Ernexa Therapeutics' Change in Receivables (Quarter) stood at -$4000.0 in 2021, then surged by 725.0% to $25000.0 in 2022, then crashed by 5508.0% to -$1.4 million in 2023, then skyrocketed by 118.49% to $250000.0 in 2024, then tumbled by 100.4% to -$1000.0 in 2025.
  • Its Change in Receivables was -$1000.0 in Q3 2025, compared to -$2000.0 in Q2 2025 and -$281000.0 in Q1 2025.